DVAX - Dynavax Technologies Corporation
9.52 0.00 (0.00%)
After hours: 5:01PM EST
| Previous Close | 10.15 |
| Open | 10.30 |
| Bid | 9.20 x 1200 |
| Ask | 10.32 x 800 |
| Day's Range | 9.26 - 10.32 |
| 52 Week Range | 9.26 - 22.80 |
| Volume | 1,068,518 |
| Avg. Volume | 1,186,103 |
| Market Cap | 596.823M |
| Beta (3Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.60 |
- Insider Monkey•2 days ago
Is Dynavax Technologies Corporation (DVAX) Going to Burn These Hedge Funds?
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of DVAX earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Dynavax Technologies Corp Earnings Call
- Motley Fool•last month
Why Dynavax Technologies Corporation Fell 20.2% in October
Preliminary data that looked good on the surface left investors with more questions than answers.
- Associated Press•last month
Dynavax Technologies: 3Q Earnings Snapshot
The Berkeley, California-based company said it had a loss of 65 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for.
- Motley Fool•last month
Don't Waste Your Money on Penny Stocks; These 3 Stocks Are Better Buys
If you're looking for high-reward stocks, these three could pay off big.
- GlobeNewswire•2 months ago
Dynavax to Host Third Quarter 2018 Financial Results Conference Call
BERKELEY, Calif., Oct. 29, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September.
- Zacks•2 months ago
Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Motley Fool•2 months agoWhy American Railcar Industries, PetMed Express, and Dynavax Technologies Jumped Today
Find out which of these companies got a buyout bid.
- Motley Fool•2 months ago
Why Dynavax Technologies Corporation Is Surging Today
Encouraging clinical data helps the beaten-down biotech to recover.
- GlobeNewswire•2 months ago
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative.
- ACCESSWIRE•2 months ago
Medical Companies You Need to Have on Your Radar
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Below are a few Medical stocks that are in position to make their investors major profit in the coming sessions.The company on our radar today, however, ...
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
Dynavax Technologies Corporation (DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. SD-101 is expected to augment responses to anti-PD-1 therapy as has been reflected in early clinical studies of other tumor types.
- Benzinga•2 months ago
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
- ACCESSWIRE•2 months ago
Major Biotech Announcements Moving the Market
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
- InvestorPlace•2 months ago
ARWR Stock Sinks After Signing a Big Collaboration Deal
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
- GlobeNewswire•2 months ago
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
BERKELEY, Calif., Oct. 09, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating.
- Motley Fool•2 months ago
Why Dynavax Technologies Corporation Stock Struggled in September
Dynavax's shares kept losing ground last month, but a turnaround could be close at hand.
American City Business Journals•3 months agoHealth Care Digest: An East Bay biotech coup, a Nobel effort and an A's bobblehead
Nobel Prize winner Jim Allison is in Texas, but the Nobel Prize win Monday for his cancer immunotherapy work reverberates in the Bay Area.
- Motley Fool•3 months ago
3 Top Stocks That Aren't on Wall Street's Radar
From two intriguing small-cap stocks to a large-cap play, here are three stocks calling for your attention.
- GlobeNewswire•3 months ago
Dynavax to Present at the 2018 Cantor Global Healthcare Conference
BERKELEY, Calif., Sept. 27, 2018-- Dynavax Technologies Corporation today announced that Eddie Gray, Dynavax’ s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on ...
